Radius slips after Phase I readouts for SERM program

Radius Health Inc. (NASDAQ:RDUS) lost $6.43 (12%) to $47.07 on Thursday after announcing early data from two Phase I trials of RAD1901 to treat estrogen receptor (ER)-positive breast cancer.

In a safety expansion cohort of a U.S. Phase Ib trial, RAD1901 led to confirmed partial responses (PRs) in two of 20 heavily pretreated ER-positive, HER2-negative advanced breast cancer patients...